Blinatumomab, a CD19/CD3 BiTE, has been approved in the R/R B-cell precursor acute lymphocytic leukemia (ALL) based on the Phase III TOWER study that demonstrated improved overall survival (OS) and complete remission (CR) when compared to standard of chemotherapy [5, 6]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.